Elevance Health Faces Antitrust Suit Over Out-of-Network Penalties
Elevance Health is facing an antitrust lawsuit over its out-of-network penalty policy. A Long Island neurological surgery practice filed the case on Sept. 17, captioned Neurological Surgery Practice of Long Island, PLLC v. Elevance Health Inc. et al., alleging that the policy violates federal and state antitrust laws. Becker's Payer Issues reported the filing the next day.
The legal theory matters here. Payer disputes usually turn on contract language or state insurance rules. Antitrust law, which exists to protect competition, moves the question elsewhere: toward whether a policy distorts competition in the market, rather than whether it follows the terms of a provider agreement. That is a harder argument to win, and a broader one. Readers should watch the complaint's market definitions, since they determine whether the claim reaches beyond one practice.
Elevance has also been involved in a separate surprise billing dispute in California. A judge there tossed the company's surprise billing suit involving HaloMD, according to Healthcare Dive, which reported the ruling on April 14, 2026. Anthem Blue Cross had filed the California action against HaloMD and providers in July 2025.
The headline figures this week come from a different corner of the market. The Wall Street Journal reported that The Perfect Child, an autism-therapy provider, billed $30,000 a day, and that the FBI is investigating its billing practices (WSJ). Both outlets reported the story on Nov. 3, 2026. Quartz reported that FBI agents interviewed a woman who was billed $911,000 by the company and obtained company records. Quartz also reported that insurers and a House committee are investigating the provider.
The Perfect Child also sued a customer named Wu in an effort to collect about $20,000, according to the WSJ. Wu said he later settled with the company.
In my view, one settlement says little about the broader pattern. It does show how a billing dispute can move from a claims desk into collections and litigation.
In my view, the daily figure deserves a careful reading. A $30,000 daily charge is a billed amount, known as a gross charge. Whether any payer paid it, and in what amounts, is a different question, answered by net reimbursement, which is what the payer actually pays. Keep the two apart when you see headline numbers of this kind.
Elevance has also taken a position on its quality ratings. The company claims that a disparity in its 2026 star ratings will cost it about $115 million in 2027 quality bonus payments, Becker's Payer Issues reported on July 2, 2026.
In my view, the $115 million figure is a projection, not a reported result. It is the company's own estimate of a future payment effect, and it depends on how the star ratings translate into payments in 2027.
In my view, these items are not one story. Each runs on its own clock, and each will change how investors and analysts model Elevance's revenue exposure only as its specifics become clearer.
The antitrust complaint is at the pleading stage, the early phase in which the court tests the claims as written. The California ruling has already been issued. The FBI probe concerns a provider, not a payer's pricing, and it is still open. The $115 million figure is a forecast for a payment year that has not started.
For now, the narrower conclusion is that Elevance faces litigation over out-of-network penalties, has lost one surprise billing suit in California, and has put a specific dollar estimate on its 2027 star ratings exposure.
